Janux Therapeutics Inc.
JANX | NASDAQ
$17.01
+$0.42 (+2.53%)
At close: Sep 21, 2026, 4:00 PM ET
$17.10
+$0.09 (+0.53%)
Pre-market:
Sep 22, 2026, 8:33 AM ET
Market Data
Market Cap $1.04B
Enterprise Value $87.42M
Beta 2.52
Average Volume 984.94K
Shares Outstanding (Diluted) 62.94M
Shares Change YoY 1.67%
Institutional Ownership 95.09%
Exchange NASDAQ
ISIN US47103J1051
Price Performance
Price Change 1M -4.1%
Price Change 3M 14.1%
Price Change 6M 23.3%
Price Change YTD 24.6%
Price Change 1Y -27.6%
Price Change 3Y 77.2%
Price Change 5Y -17.8%
1M CAGR (ann.) 7.3%
1Y CAGR (ann.) -30.3%
5Y CAGR (ann.) -9.7%
All-Time CAGR -7.1%
Valuation
PE Ratio -10.37
Forward PE N/A
PEG Ratio -1.46
Forward PEG -0.20
PS Ratio 32.54
Forward PS 119.00
PB Ratio 1.12
P/FCF Ratio -19.02
P/Adj. FCF Ratio -10.30
P/OCF Ratio -20.01
EV/Sales 2.74
EV/EBIT -0.85
EV/EBITDA -0.86
EV/FCF -1.60
Earnings Yield -9.6%
FCF Yield -5.3%
Adj. FCF Yield -9.7%
Financial Health
Net Cash $949.92M
Total Debt $20.99M
Cash & Short-Term Investments $970.91M
Total Assets $1.01B
Current Ratio 16.35
Quick Ratio 16.35
Debt / Equity Ratio 0.02
Debt / EBITDA -0.21
Debt / FCF -0.38
OCF / Debt -2.55
Interest Coverage 0.00
Altman Z-Score 8.05
Piotroski F-Score 4
Margins & Profitability
Gross Profit Margin 68.9%
Operating Profit Margin -450.3%
EBITDA Margin -317.1%
Net Profit Margin -321.8%
FCF Margin -171.1%
Adj. FCF Margin -315.9%
SBC / Revenue 144.8%
SBC Impact (per share) -84.6%
Returns
Return on Assets -10.2%
Return on Equity -10.8%
Return on Invested Capital -15.1%
Return on Capital Employed -15.2%
Return on Tangible Assets -10.2%
Historical Growth (CAGR)
Revenue CAGR 3Y 60.1%
Revenue CAGR 5Y 105.9%
Revenue CAGR 10Y N/A
EPS CAGR 3Y -25.2%
EPS CAGR 5Y -6.2%
EPS CAGR 10Y N/A
FCF CAGR 3Y -6.3%
FCF CAGR 5Y -6.9%
FCF CAGR 10Y N/A
Analyst Forecasts
Analyst Rating Buy
Analyst Count 16
EPS Growth Next 3Y -41.7%
Revenue Growth Next 3Y 16.5%
Earnings Date Nov 4, 2026
EPS Estimate (next Q) -$0.45
EPS Growth Est (next Q) 15.4%
Revenue Est (next Q) $8.03M
Revenue Growth Est (next Q) -19.7%
Fair Value Estimates
Graham Number N/A
Graham Upside N/A
Lynch Fair Value N/A
Lynch Upside N/A
Price Target $28.25
Price Target Upside 66.1%
Cash Flow
Operating Cash Flow $-53.59M
Free Cash Flow $-54.54M
Adj. Free Cash Flow $-100.69M
FCF Per Share -$0.87
OCF Per Share -$0.85
OCF/S Ratio -168.1%
Income Statement
Revenue $31.88M
Gross Profit $21.97M
Operating Income $-143.56M
EBITDA $-101.1M
Net Income $-102.59M
EPS (Diluted) -$1.64
Revenue / Employee $282.12K
Profit / Employee $-907.89K
Employees 113
Add to Watchlist
Select watchlists to add or remove JANX